Cortexyme’s $125 Million Private Placement

Orrick Herrington & Sutcliffe LLP has advised San Francisco-based biopharmaceutical company Cortexyme (Nasdaq: CRTX) on its $125 million private placement of common stock.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has closed its private placement offering. The Company issued 2,500,000 shares of common stock for a purchase price of $50.00 per share, resulting in gross proceeds to the Company of $125 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement primarily to advance clinical development, as well as for general corporate purposes.

Cortexyme plans to use the net proceeds from the private placement to advance clinical development, as well as for general corporate purposes. BofA Securities and Jefferies served as placement agents for the private placement, and Canaccord Genuity LLC, JMP Group LLC and LifeSci Capital LLC served as financial advisors.

The Orrick team advising Cortexyme included Scott Iyama (Picture), Niki Fang and Brigid McCurdy.

Involved fees earner: Niki Fang – Orrick; Scott Iyama – Orrick; Brigid McCurdy – Orrick;

Law Firms: Orrick;

Clients: Cortexyme Inc.;